AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.06 -1.88%

-$1.07 today

Market cap
$1.40B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.57M

Average 0.76M

ANAB Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

AnaptysBio, Inc.NASDAQ: ANAB

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 44.0% from a year ago

Net receivables stood at $25.75M at the end of Q1 FY2026, up 44.0% from a year earlier and down 23.9% from the prior quarter. Over 3 fiscal years it compounded at +187.9% a year.

Context

  • Net receivables amounted to 7.8% of total assets at the end of Q1 FY2026, up 3.6 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +44.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$25.75M-23.9% QoQ
Last fiscal yearDec 2025
$33.85M-17.0% YoY
Year agoMar 2025
$17.88M+44.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+44.0%——
1 year-17.0%——
3-year CAGR+187.9%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
33.85M USD
Year-over-year change
-17.0%
4-year CAGR
+149.3%

Net Receivables vs competitors

How ANAB compares with its peers on the latest reported figures

  • ANAB's Mar 2026 net receivables of $25.75M is the 2nd highest of the 10 companies compared; the peer median is $161K.
  • Its year-over-year change of +44.0% is the 4th highest of 9, against a peer median of -26.6%.
  • Net receivables amounts to 7.8% of total assets for ANAB, versus a peer median of 0.3%.
ANAB Competitors Peer median
Net Receivables for ANAB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
XNCRXencor, Inc.Jun 2026$42.23M -11.2%+0.3%5.8%
ANABAnaptysBio, Inc.Mar 2026$25.75M +44.0%+187.9%7.8%
MLTXMoonLake ImmunotherapeuticsMar 2026$5.76M +92.9%+182.0%1.4%
ACRSAclaris Therapeutics, Inc.Mar 2026$4.81M +1825.6%+125.7%2.4%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$600K -42.0%+13.5%0.6%
CNTBConnect Biopharma Holdings LimitedDec 2025$161K -84.7%-11.5%0.3%
IMVTImmunovant, Inc.Sep 2026$138K -93.0%+64.6%0.0%
DNTHDianthus Therapeutics, Inc.Jun 2026$106K +171.8%-73.7%0.0%
ANNXAnnexon, Inc.Mar 2026$0 ——0.0%
QTTBQ32 Bio Inc.Mar 2026$0 -100.0%—0.0%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ANAB) $161K-26.6%+13.5%0.3%

Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents495.73M71.31M35.97M123.08M238.2M
Short-term Investments52.37M369.93M354.94M262.29M73.44M
Net Receivables876K1.42M6.85M40.77M33.85M
Inventory00000
Other Current Assets04.55M9.08M5.74M4.76M
Total Current Assets553.88M447.21M406.84M431.88M350.25M
Property, Plant & Equipment (Net)21.84M19.99M18.27M16.23M13.89M
Goodwill00000
Intangible Assets00000
Long-term Investments67.1M142.94M27.03M35.47M0
Tax Assets00000
Other Non-current Assets256K256K256K256K256K
Total Non-current Assets89.19M163.18M45.55M51.96M14.15M
Total Assets643.07M610.38M452.39M483.83M364.4M
Account Payables1.74M2.78M4.7M4M3.87M
Short-term Debt0001.93M0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.18M5.38M23.77M31.05M11.09M
Total Current Liabilities16.1M26.05M37.44M45.43M38.63M
Long-term Debt000353.43M12.03M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities251.09M304.41M310.81M0276.53M
Total Non-current Liabilities270.54M322.23M326.84M367.54M288.56M
Total Liabilities286.64M348.28M364.29M412.97M327.19M
Common Stock28K29K27K30K28K
Retained Earnings(321.75M)(450.48M)(614.1M)(759.33M)(772.56M)
Accumulated OCI(422K)(5.25M)(797K)305K(24K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity356.43M262.1M88.1M70.87M37.21M
Total Debt20.96M19.45M17.81M369.46M14.11M
Net Debt(474.77M)(51.86M)(18.15M)246.38M(224.08M)

AnaptysBio, Inc.

NASDAQ:ANAB

Intrinsic Alpha fair value

Locked

Current Price

$47.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.